Gevo, Inc:Announces pricing of $10 million public offering of common stock and warrants.Agreed to sell 8 million series b units.Agreed to sell 2.1 million series a units, with each series a unit consisting of one share of common stock and a series d warrant.Agreed to sell 2.1 million series a units to purchase one share of common stock at a public offering price of $1.00 per series a unit.
Gevo:Intends to offer and sell, subject to market and other conditions, Series A units, with each Series A unit consisting of one share of common stock and Series D warrants to purchase a certain number of shares of common stock.Company is also offering Series B units, in lieu of Series A units, to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 4.99% of Co's outstanding common stock following completion of offering.The Series B units will consist of pre-funded warrants to purchase one share of common stock and Series D warrants to purchase a certain number of shares of common stock.The units are to be sold by Gevo subject to market and other conditions in an underwritten public offering.Gevo currently intends to use the net proceeds from the offering, excluding any future proceeds from the exercise of the warrants, to fund working capital, including capital expenditures at the Luverne, MN facility, and for other general corporate purposes.In connection with the offering, Oppenheimer & Co. Inc. is acting as sole book-running manager.
Deinove SA:Announces capital increase, with shareholders' preferential subscription rights, of about 9.3 mln euros to finance its new momentum and industrialize its bioprocesses.Subscription parity is one new share for three existing shares.Subscription price is 4.50 euros per share.Subscription period to last from Nov. 30 to Dec. 14 inclusive.Subscription commitments are 5.5 mln euros.Says proceeds of issue will be used to give company financial means to finance acceleration of its development and industrialization of its bioprocesses, both in biofuels and biochemical.
SOLARVEST BIOENERGY INC:closed a non-brokered private placement, pursuant to which an investor purchased from the Company 400,000 Units at a price of $0.25 per Unit for gross proceeds of $100,000.Each Unit consists of one common share and one warrant.Each warrant is exercisable for one common share at $0.35 for a period of eighteen months following closing and include an acceleration clause that is triggered by a share price of $0.55 per share.Proceeds from this private placement will be used as general working capital.shares will be subject to resale restrictions for a period of four months from closing under applicable securities legislation.
JC Chemical Co Ltd:Priced its 6,003,000 new shares that will be offered in a rights issue, was determined at 2,155 won per share.To raise proceeds of 11,584,465,000 won for other funds and 1,352,000,000 won for facilities.